Chan, Andrew T <br/><br/>
Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.  [electronic resource] 

 -  Gastroenterology  Jun 2009 
 - 2127-2136.e1 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0012 
<br/><br/><label>Standard No.: </label>10.1053/j.gastro.2009.02.045  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenoma--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Aryl Hydrocarbon Hydroxylases--drug effects<br/>Celecoxib<br/>Colorectal Neoplasms--drug therapy<br/>Confidence Intervals<br/>Cytochrome P-450 CYP2C9<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Genetic Predisposition to Disease<br/>Genetic Variation<br/>Genotype<br/>Humans<br/>Male<br/>Middle Aged<br/>Pharmacogenetics<br/>Probability<br/>Pyrazoles--therapeutic use<br/>Reference Values<br/>Risk Assessment<br/>Sensitivity and Specificity<br/>Sulfonamides--therapeutic use<br/>Treatment Outcome